Automate Your Wheel Strategy on SRZNW
With Tiblio's Option Bot, you can configure your own wheel strategy including SRZNW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SRZNW
- Rev/Share 2.9369
- Book/Share 1.5639
- PB 5.1984
- Debt/Equity 1.4043
- CurrentRatio 10.018
- ROIC -0.2462
- MktCap 69613775.0
- FreeCF/Share -5.0185
- PFCF -3.8235
- PE -0.361
- Debt/Assets 0.0694
- DivYield 0
- ROE 82.1765
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About Surrozen, Inc. (SRZNW)
- IPO Date 2021-08-10
- Website http://www.surrozen.com
- Industry Biotechnology
- CEO Mr. Craig C. Parker M.B.A.
- Employees 40
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are highly expressed in intestinal crypts. The company was founded in 2016 and is headquartered in South San Francisco, California.